Literature DB >> 10913021

Hyperinsulinemia compensates for infection-induced impairment in net hepatic glucose uptake during TPN.

C M Donmoyer1, S S Chen, S A Hande, D B Lacy, J Ejiofor, O P McGuinness.   

Abstract

In animals receiving total parenteral nutrition (TPN), infection impairs net hepatic glucose uptake (NHGU) by 40% and induces mild hyperinsulinemia. In the normal animal, the majority of the glucose taken up by the liver is diverted to lactate, but in the infected state, lactate release is curtailed. Because of the hyperinsulinemia and reduced NHGU, more glucose is utilized by peripheral tissues. Our aims were to determine the role of infection-induced hyperinsulinemia in 1) limiting the fall in NHGU and hepatic lactate release and 2) increasing the proportion of glucose disposed of by peripheral tissues. Chronically catheterized dogs received TPN for 5 days via the inferior vena cava. On day 3, a fibrin clot with a nonlethal dose of E. coli was placed into the peritoneal cavity; sham dogs received a sterile clot. On day 5, somatostatin was infused to prevent endogenous pancreatic hormone secretion, and insulin and glucagon were replaced at rates matching incoming hormone concentrations observed previously in sham or infected dogs. The TPN-derived glucose infusion was adjusted to maintain a constant arterial plasma glucose level of approximately 120 mg/dl. after a basal blood sampling period, the insulin infusion rate was either maintained constant (infected time control, Hi-Ins, n = 6; sham time control, Sham, n = 6) or decreased (infected + reduced insulin, Lo-Ins; n = 6) for 180 min to levels seen in noninfected dogs (from 23 +/- 2 to 12 +/- 1 microU/ml). Reduction of insulin to noninfected levels decreased NHGU by 1.4 +/- 0.5 mg x kg(-1) x min(-1) (P < 0.05) and nonhepatic glucose utilization by 4.8 +/- 0.8 mg x kg(-1) x min(-1) (P < 0.01). The fall in NHGU was caused by a decline in HGU (Delta-0.6 +/- 0.4 mg x kg(-1) x min(-1)) and a concomitant increase in hepatic glucose production (HGP, Delta0.8 +/- 0.5 mg x kg(-1) x min(-1)); net hepatic lactate release was not altered. Hyperinsulinemia that accompanies infection 1) primarily diverts glucose carbon to peripheral tissues, 2) limits the fall in NHGU by enhancing HGU and suppressing HGP, and 3) does not enhance hepatic lactate release, thus favoring hepatic glucose storage. Compensatory hyperinsulinemia plays a critical role in facilitating hepatic and peripheral glucose disposal during an infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913021     DOI: 10.1152/ajpendo.2000.279.2.E235

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  4 in total

1.  Rapid changes in the microvascular circulation of skeletal muscle impair insulin delivery during sepsis.

Authors:  Nicholas A Mignemi; P Mason McClatchey; Kameron V Kilchrist; Ian M Williams; Bryan A Millis; Kristen E Syring; Craig L Duvall; David H Wasserman; Owen P McGuinness
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-03-12       Impact factor: 4.310

2.  Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine.

Authors:  Dale S Edgerton; Alan D Cherrington; Doss W Neal; Melanie Scott; Margaret Lautz; Nancy Brown; Jeff Petro; Charles H Hobbs; Chet Leach; Angelo Del Parigi; Thomas R Strack
Journal:  J Pharmacol Exp Ther       Date:  2008-12-19       Impact factor: 4.030

3.  Elevated plasma free fatty acid concentrations do not modify cardiac repolarization in patients treated by electrolyte-glucose-insulin infusion.

Authors:  F Nappo; M Loreto; G Giugliano; E Grella; K Esposito; B Lettieri; D Giugliano
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

4.  Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

Authors:  Dale S Edgerton; Kathryn M S Johnson; Doss W Neal; Melanie Scott; Charles H Hobbs; Xia Zhang; Alokesh Duttaroy; Alan D Cherrington
Journal:  Diabetes       Date:  2008-10-07       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.